Treatment Outcomes and Prognostic Factors in Adult Astrocytoma: In North East of Iran

Abstract

BackgroundAstrocytomas are the most common primary adult brain tumors.ObjectivesIn this study, we investigated the impact of some potential prognostic factors on survival in patients with low and high grade astrocytomas.Patients and MethodsThis retrospective cohort study was performed on patients with brain astrocytoma who were referred to oncology departments, Omid and Ghaem hospitals, Mashhad University of Medical Sciences (2000 - 2011).Results415 patients with a median age of 43 and a male to female ratio of 252:163 (1.54) were recorded. Grade I to IV astrocytoma were found in 40 (9.6%), 88 (21.2%), 71 (17.1%) and 216 (52%) patients. With a median follow up time of 37 months for low grade and 13 months for high grade astrocytoma, the 5-year survival in grades I to IV was 92.1%, 69.1%, 49.2% and 9.6% respectively. In low grade astrocytomas, patients with grade I tumors, being ambulatory (5-year survival: 88% vs. 60.3%, P < 0.001) and performing optimal surgery (5-year survival 86% vs. 59.3%, P < 0.001) were associated with more favorable survival. In high grade astrocytomas, patients with grade III tumors, age < 50 (5-year survival 29.6% vs. 14.6%, P < 0.001), being ambulatory (5-year survival 39.4% vs. 10.5, P < 0.001), performing optimal surgery (5-year survival 46.1% vs. 4.3%, P < 0.001) and receiving chemotherapy (5-year survival 23.7% vs. 18.7%, P = 0.02) were associated with significantly higher overall survival.ConclusionsPerforming optimal surgery and good performance status were associated with more favorable survival in both low and high grade astrocytomas. In high grade a strocytomas, patients younger than 43 and those who received chemotherapy had better overall survival.

Comprehensive analysis of Iranian reports of pediatric central nervous system tumors

“…The study objectives were categorized as clinical (n = 18 articles, 173 patients), epidemiologic (n = 9 articles [5, 8, 12–13, 16, 26, 28, 33–34], 1,881 patients), pathologic (n = 4 articles [11, 14, 15, 18], 1,160 patients), genetic (n = 2 articles [7, 30], 75 patients), surgical (n = 1 article [21], 172 patients), or radiologic (n = 1 article [29], 23 patients). Study designs were primarily single case reports (n = 16 articles [2–4, 9, 16–17, 19–22, 24, 29, 31–32, 36–37], 19 patients) and cross-sectional studies (n = 15 articles [7–8, 10–14, 15, 18, 25–26, 28, 30, 33–34], 3,271 patients).…”

“…Study designs were primarily single case reports (n = 16 articles [2–4, 9, 16–17, 19–22, 24, 29, 31–32, 36–37], 19 patients) and cross-sectional studies (n = 15 articles [7–8, 10–14, 15, 18, 25–26, 28, 30, 33–34], 3,271 patients). Other study designs included cohort (n = 2 articles [23, 35], 131 patients), case series (n = 1 article [5], 7 patients), and case control (n = 1 article [27], 56 patients) (Table 1).…”

Modern tactics of treatment of malignant glyom of the brain and the case of the complete answer of the tumor on the background of the long-term reception of bevacizumab

“…Глиомы представляют собой наиболее распростра-ненный и агрессивный тип первичной опухоли у взрос-лых [1,2,3,4]. Так, на них приходится до 70% всех видов злокачественных новообразований головного мозга [5,6], при этом опухоли головного мозга находятся на 3-м ме-сте по темпам роста заболеваемости среди всех онколо-гических новообразований [7].…”

“…Традиционно стандартом лечения глиом высокой сте-пени анаплазии головного мозга является максимально безопасная хирургическая резекция [3,15] с последую-щей адъювантной лучевой или химиолучевой терапией [15]. Рекомендательный характер носит применение хи-миотерапии темозоламидом.…”

A novel cell-permeable RDP-p53 fusion protein for specific inhibition on the growth of cancerous neural cells

“…The 5-year survival rate of patients with brain cancer is only 33.3% and even lower in malignant glioma (Anvari et al, 2014). Although surgical resection combined with radiotherapy and chemotherapy is effective temporarily, it is difficult to completely remove the tumor due to the infiltrate growth of cancers, as well as lost brain function that may result from injuries after resection (Pardridge, 2012;Singh & Subudhi, 2014).…”